Trial
NCT02874651
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
First People's Hospital of Foshan; Guilin Medical University, China
Condition
Nasopharyngeal Neoplasms
Intervention
Apatinib
Why stopped
Unacceptable toxicity (nasopharynx necrosis and massive hemorrhage)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-11